- App Portal
Medications to Reduce the Risk of Primary Breast Cancer in Women: Clinician's Guide
This guide for clinicians summarizes evidence on the effectiveness and safety of two medications used to reduce the risk of primary breast cancer: tamoxifen and raloxifene. Both of these medications are approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of primary breast cancer (defined as invasive breast cancer in women without preexisting breast cancer). However, currently they are rarely used for this purpose in the United States. This toolkit is available as PDF (requiring Adobe Reader) and as an audio file (MP3). It was developed by Agency for Healthcare Research and Quality (AHRQ), John M. Eisenberg Center at Oregon Health and Science University.